Stoke Therapeutics Inc Asset Resilience Ratio
Stoke Therapeutics Inc asset resilience ratio. Stoke Therapeutics Inc (STOK) has an Asset Resilience Ratio of 46.40% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Stoke Therapeutics Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Stoke Therapeutics Inc (2017–2025)
Asset resilience ratio of Stoke Therapeutics Inc from 2017 to 2025. This chart shows how Stoke Therapeutics Inc's Asset Resilience Ratio has changed over time. Read how much debt does Stoke Therapeutics Inc carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Stoke Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Stoke Therapeutics Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $182.81 Million | 46.4% |
| Total Liquid Assets | $182.81 Million | 46.40% |
Asset Resilience Insights
- Very High Liquidity: Stoke Therapeutics Inc maintains exceptional liquid asset reserves at 46.40% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Stoke Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Stoke Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Stoke Therapeutics Inc Asset Resilience Ratio by Year (2017–2025)
Stoke Therapeutics Inc asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Stoke Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 47.90% | $200.45 Million | $418.43 Million | +15.16pp |
| 2024-12-31 | 32.74% | $88.92 Million | $271.56 Million | +28.38pp |
| 2023-12-31 | 4.36% | $9.95 Million | $228.34 Million | -40.96pp |
| 2022-12-31 | 45.32% | $116.04 Million | $256.07 Million | +13.95pp |
| 2021-12-31 | 31.36% | $74.92 Million | $238.87 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $297.93 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $107.54 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $2.44 Million | -- |
About Stoke Therapeutics Inc
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials fo… Read more